



Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
October 19, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[* Click HERE for Meeting Documents *](#)

Board Members Present

Charlene Heyde, PharmD
Jennifer Passanise, FNP-BC
Julie Ferguson, DO
Kimberly Eisenstein, MD
Lisa Pierce, MD
Sandra Bollinger, PharmD
Stacy Mangum, PharmD
Susan Abdel-Rahman, PharmD

Board Members Absent

Ginger Nicol, MD, CEDS
Rick Kegler, PharmD

MO HealthNet Staff Present

Angela Wilson, Pharmacy Program Manager
Carmen Burton, Pharmacy Support Assistant
Connie Sutter, Fiscal Manager
Elizabeth Short, Program Development Specialist
Elizabeth Sissom, RN, Clinical Review Nurse
Joshua Moore, PharmD, Director of Pharmacy
Lisa Hogg, Special Counsel
Lisa Smith, Pharmacy RFP Coordinator
Mark Roaseau, R.Ph, Clinical Pharmacist
Olivia Rush, PharmD, Program Integrity Pharmacist
Racheal Rachau, Pharmacy Benefit Specialist
Timothy Kling, MD, Acting Medical Director

Contractors Present

Amanda Williams, PharmD, RPh, GWT
Amy Cully, PharmD, Conduent
Ashley Lytton, RN, BSN, Wipro
Chelsea Pendleton, RN, BSN, Wipro
Dimple Patel, Conduent
Geri Roling, RN, Wipro
Jennifer Colozza, PharmD, Conduent
Karen Powell, PharmD, MS, GWT
Leanna Kirsch, RN, Wipro
Mary-Beth Plum, PharmD, Conduent
Megan Fast, PharmD, GWT
Paul Fung, PharmD, MHA, Conduent
PhuongLinh Morsches, PharmD, Conduent
Sandy Kapur, PharmD, GWT
Serena Barden, PharmD, BCPS, GWT
Shefali Patel, PharmD, Wipro
Vicki Revel, GWT

Others Present:

Alina Triasucheva
Angela Hailes
Ashlee
Bobbi Bentz
Brian Strickland
Brooke Wilkins
Carrie Davis
Dominick De Wolf
Erin Hohman
Garth Wright

James Baumann
Jenny Carrell
Jessica Petrie
Lisa Tracz
Michael Holmes
Michelle Schnarre
Nancy Njuguna
Patty Minear
Pete Bush
Richie Crawford

Ricki Roberson
Rob Kilo
Robin Selsor
Rusty Hailey
Sean Jones
Shauna Williams
Stephanie Michel
Tami Sova

DRAFT

<p>Welcome, Announcements and Introductions</p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with Sandy Kapur and Amanda Williams, both with Gainwell and PhuongLinh Morsches, Amy Cully and Dimple Patel, all with Conduent. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the July meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - August 2022 Enrollees and Expenditures - July – August 2022 Expenditures by Service - FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures - Oct 2021 – Aug 2022 Medicaid Expansion Participants, Expenditures, and Claim Count - Pharmacy Program Top 4 Drug Classes per FY - July 2022 – October 2022 Pharmacy Expenditures - July 2022 – October 2022 Pharmacy Specialty and Non-Specialty Expenditures - July 2019 – October 2022 Mavyret Expenditures - September 2022 Top Ten Reimbursed Drugs for Children 0-17 - January 2022 – October 2022 Per User Per Month Drug Claim Reimbursement - FY2020 – FYTD2023 Rare Disease Expenditures Per Day - Additional updates were provided on: <ul style="list-style-type: none"> o Clinical initiatives <ul style="list-style-type: none"> ▪ GCMs ▪ Tubeless insulin pumps ▪ Naloxone and High Risk Therapies Clinical Edit o Project Hep Cure Dashboard <ul style="list-style-type: none"> ▪ MHD to bring back utilization data for the dashboard o State Plan Amendment for Value Base Agreement o Upcoming Webinar CE/CME

Old Business

Old Business

Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.

These handouts were also provided to all attendees and will be posted to the Division's web page: <https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm>

Elizabeth Sissom gave a brief update on initiatives that were recently implemented.

New Business

New Drug Review

Discussion:

- Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program.
 - o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action.
- No other discussion.
- No public comment provided.

Decision: The Board voted to accept the presented new drug recommendations with no revisions.

Clinical and Fiscal Edit Review

<p>Clinical & Fiscal Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none">- Joshua Moore introduced the edits for discussion to the Board which included:<ul style="list-style-type: none">o Entrestoo Spinal Muscular Atrophy (SMA)- No other discussion.- No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Alpelisib Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none">- Joshua Moore introduced the edit for discussion to the Board.- No other discussion.- No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none">- Joshua Moore introduced the edit for discussion to the Board.- No other discussion.- No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Preferred Drug List Edit Review

Preferred Drug Edits With No Annual Changes

Discussion:

- Joshua Moore introduced the edits for discussion to the Board which included:
 - o ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations
 - o ACE-Inhibitors/Calcium Channel Blocker Combinations
 - o ADHD, Methylphenidate, Short Acting
 - o ADHD, Non-Stimulants
 - o Alpha-Glucosidase Inhibitors
 - o Amylin Analogs
 - o Antibiotics, Mupirocin Topical
 - o Antihyperuricemic Agents
 - o ARBs and ARBs/Diuretic Combinations
 - o ARBs/Calcium Channel Blocker Combinations
 - o Benign Prostatic Hyperplasia (BPH) Agents
 - o Beta Blockers & Beta Blockers/Diuretic Combinations
 - o Biguanides & Combinations
 - o Bone Ossification Agents
 - o Calcium Channel Blockers, Non-Dihydropyridines
 - o Cephalosporin Agents
 - o Direct Renin Inhibitors & Combinations
 - o DPP-IV Inhibitors & Combinations
 - o Electrolyte Depleting Agents, Phosphate Lowering
 - o Erythropoiesis Stimulating Agents
 - o Fluoroquinolone Agents, Oral
 - o Homozygous Familial Hypercholesterolemia (HoFH) Agents
 - o Insulin, Mixed
 - o Insulin, Non-Analogs
 - o Insulin, Rapid Acting
 - o Macrolides
 - o Meglitinides
 - o Methotrexate Agents
 - o Niacin Derivatives

	<ul style="list-style-type: none"> ○ Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRAAs) ○ Pulmonary Arterial Hypertension (PAH) Agents, PDE5-Inhibitors and SGC Stimulators ○ Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Oral ○ Penicillin Agents ○ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents ○ Statins (HMG-CoA Reductase Inhibitors) & Combinations ○ Sulfonylureas, Second Generation ○ Tetracycline Agents ○ Thiazolidinediones & Combinations ○ Thrombocytopenia Agents ○ Triglyceride Lowering Agents <ul style="list-style-type: none"> - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>ADHD, Amphetamines Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>ADHD, Amphetamines, Short Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>ADHD, Methylphenidate Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Antibiotics, GI Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antibiotics, Vaginal PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticoagulants, Oral and Subcutaneous PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticonvulsants, Rescue Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Bile Salt Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Calcium Channel Blockers, Dihydropyridines PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Colony Stimulating Factors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Cryopyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Dry Eye Disease Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Electrolyte Depleting Agents, Potassium Lowering PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Erythropoiesis Stimulating Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Growth Hormone Agents, Somatropin PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>No public comment provided.</p> <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Insulin, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Multiple Sclerosis Agents, Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Multiple Sclerosis Agents, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Binders PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Proton Pump Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Inhaled PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Sympatholytic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Targeted Immune Modulators, IL6 Receptor Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with additional revisions to the wording of the chronic rhinosinusitis with nasal polyposis systemic corticosteroid therapy criteria.</p>
<p>Targeted Immune Modulators, Select Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, TNF Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Urinary Tract Antispasmodics PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Other Business</p>	
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 4th Quarter 2022 (April, May, June) - Top 25 Drugs by Paid Number 4th Quarter 2022 (April, May, June) - Call Center User Statistics August 2022 - CyberAccess Logging Information - New Drug Statistics August 2022
<p>RetroDUR Update</p>	<p>Amy Cully with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Recent RetroDUR Interventions: <ul style="list-style-type: none"> o Concurrent Use of Opioids and Stimulants o Hepatitis C – Project Hep Cure o Overutilization of Short-Acting Beta Agonist - Current RetroDUR Interventions: <ul style="list-style-type: none"> o Preventing Overdose in Patients Using Medication-Assisted Treatment (MAT) <ul style="list-style-type: none"> ▪ Preventing Overdose in Patients Using Medication-Assisted Treatment (MAT) provider letter - Potential RetroDUR Interventions: <ul style="list-style-type: none"> o Continuous Glucose Monitors for participants with history of short acting insulin and an ER visit/admission for hypoglycemia
<p>Motion to Close</p>	<p>Lisa Pierce motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p> <p>A review of the Pharmacy Dashboard was provided during Closed Session.</p>

NEXT MEETING: Thursday, January 18, 2023
615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for October 19, 2022				
	<u>Action Item</u>			
<u>Board Member</u>	July Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y
Charlene Heyde	Y	Y	Y	Y
Sandra Bollinger	Y	Y	Y	Y
Julie Ferguson	A	Y	Y	Y
Lisa Pierce	MY	SY	MY	SY
Jennifer Passanise	Y	Y	Y	Y
Stacy Mangum	Y	MY	SY	Y
Ginger Nicol	A	A	A	A
Rick Kegler	A	A	A	A
Kim Eisenstein	SY	Y	Y	MY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain